NGNE
Price
$20.11
Change
+$0.87 (+4.52%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
316.38M
Intraday BUY SELL Signals
STOK
Price
$30.92
Change
+$1.11 (+3.72%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
1.72B
97 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NGNE vs STOK

Header iconNGNE vs STOK Comparison
Open Charts NGNE vs STOKBanner chart's image
Neurogene
Price$20.11
Change+$0.87 (+4.52%)
Volume$3.13K
Capitalization316.38M
Stoke Therapeutics
Price$30.92
Change+$1.11 (+3.72%)
Volume$16.66K
Capitalization1.72B
NGNE vs STOK Comparison Chart in %
NGNE
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NGNE vs. STOK commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a StrongBuy and STOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (NGNE: $19.25 vs. STOK: $29.79)
Brand notoriety: NGNE and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGNE: 51% vs. STOK: 26%
Market capitalization -- NGNE: $316.38M vs. STOK: $1.72B
NGNE [@Biotechnology] is valued at $316.38M. STOK’s [@Biotechnology] market capitalization is $1.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGNE’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • NGNE’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than NGNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGNE’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 7 bullish TA indicator(s).

  • NGNE’s TA Score: 4 bullish, 5 bearish.
  • STOK’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, STOK is a better buy in the short-term than NGNE.

Price Growth

NGNE (@Biotechnology) experienced а -7.18% price change this week, while STOK (@Biotechnology) price change was -0.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

STOK is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.72B) has a higher market cap than NGNE($316M). STOK YTD gains are higher at: 170.082 vs. NGNE (-15.792). STOK has higher annual earnings (EBITDA): 42.3M vs. NGNE (-81.25M). NGNE has more cash in the bank: 275M vs. STOK (248M). STOK has less debt than NGNE: STOK (2.3M) vs NGNE (12.9M). STOK has higher revenues than NGNE: STOK (200M) vs NGNE (0).
NGNESTOKNGNE / STOK
Capitalization316M1.72B18%
EBITDA-81.25M42.3M-192%
Gain YTD-15.792170.082-9%
P/E RatioN/A44.23-
Revenue0200M-
Total Cash275M248M111%
Total Debt12.9M2.3M562%
FUNDAMENTALS RATINGS
NGNE vs STOK: Fundamental Ratings
NGNE
STOK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9646
PRICE GROWTH RATING
1..100
6335
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGNE's Valuation (59) in the null industry is in the same range as STOK (81). This means that NGNE’s stock grew similarly to STOK’s over the last 12 months.

NGNE's Profit vs Risk Rating (100) in the null industry is in the same range as STOK (100). This means that NGNE’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for NGNE (96). This means that STOK’s stock grew somewhat faster than NGNE’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as NGNE (63). This means that STOK’s stock grew similarly to NGNE’s over the last 12 months.

STOK's P/E Growth Rating (4) in the null industry is significantly better than the same rating for NGNE (100). This means that STOK’s stock grew significantly faster than NGNE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGNESTOK
RSI
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
85%
Bearish Trend 6 days ago
83%
Momentum
ODDS (%)
Bearish Trend 6 days ago
81%
Bullish Trend 6 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 6 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
85%
Bullish Trend 6 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 10 days ago
86%
Declines
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 14 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NGNE
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PHSKX58.56N/A
N/A
Virtus KAR Mid-Cap Growth A
OSCCX21.44N/A
N/A
Invesco Main Street Small Cap C
AFAVX14.66N/A
N/A
AMG River Road Focused Absolute Value I
HLIZX30.44N/A
N/A
Harding Loevner International Eq Instl Z
DESUX26.84N/A
N/A
DWS ESG Core Equity R6

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
-6.01%
BRNS - NGNE
51%
Loosely correlated
-8.38%
RNAZ - NGNE
48%
Loosely correlated
-3.66%
ZNTL - NGNE
48%
Loosely correlated
-1.82%
OCUL - NGNE
47%
Loosely correlated
-3.93%
SYRE - NGNE
44%
Loosely correlated
-0.91%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-1.00%
QTTB - STOK
49%
Loosely correlated
-10.21%
NGNE - STOK
47%
Loosely correlated
-6.01%
DNLI - STOK
47%
Loosely correlated
-1.71%
SYRE - STOK
46%
Loosely correlated
-0.91%
KURA - STOK
45%
Loosely correlated
-2.53%
More